Targeting PD-L1 (Programmed death-ligand 1) and inhibiting the expression of IGF2BP2 (Insulin-like growth factor 2 mRNA-binding protein 2) affect the proliferation and apoptosis of hypopharyngeal carcinoma cells

References

• Ligier K, Belot A, Launoy G, et al. Descriptive epidemiology of upper aerodigestive tract cancers in France: incidence over 1980–2005 and projection to 2010. Oral Oncol. 2011;47(4):302–307.
   PubMed Web of Science ®Google Scholar
• Wang YL, Feng SH, Zhu J, et al. Impact of lymph node ratio on the survival of patients with hypopharyngeal squamous cell carcinoma: a population-based analysis. PLoS One. 2013;8(2):e56613.
   PubMed Web of Science ®Google Scholar
• Milliet F, Gal J, Chamorey E, et al. Total pharyngolaryngectomy in the elderly: the impact of age on postoperative complications and oncologic and functional outcomes. Surg Oncol. 2018;27(4):767–772.
   PubMed Web of Science ®Google Scholar
• Cui J, Wang L, Zhong W, et al. Development and Validation of Epigenetic Signature Predict Survival for Patients with Laryngeal Squamous Cell Carcinoma. DNA Cell Biol. 2021;40(2): 247–264.
   PubMed Web of Science ®Google Scholar
• Akbaba S, Held T, Lang K, et al. Salvage radiotherapy for recurrent hypopharyngeal and laryngeal squamous cell carcinoma (SCC) after first-line treatment with surgery alone: a 10-year single-centre experience. Radiat Oncol. 2019;14(1):34. London, England.
   PubMedGoogle Scholar
• Bar-Ad V, Palmer J, Yang H, et al. Current management of locally advanced head and neck cancer: the combination of chemotherapy with locoregional treatments. Semin Oncol. 2014;41(6):798–806.
   PubMed Web of Science ®Google Scholar
• Endo K, Masatani T, Tsuji A, et al. Thyroid dysfunction after intra-arterial chemotherapy for hypopharyngeal and laryngeal cancer. Auris Nasus Larynx. 2015;42(3):231–234.
   PubMed Web of Science ®Google Scholar
• Wakisaka N, Hirai N, Kondo S, et al. T-status and an oral fluoropyrimidine, S-1, adjuvant chemotherapy are prognostic factors in reduced-RADPLAT for resectable hypopharyngeal cancer. Acta Otolaryngol. 2016;136(8):834–840.
   PubMed Web of Science ®Google Scholar
• Blum S. Martins F and Lubbert M. Immunotherapy in adult acute leukemia. Leukemia Res. 2017;60:63–73.
   PubMed Web of Science ®Google Scholar
• Cheng F, Loscalzo J. Autoimmune cardiotoxicity of cancer immunotherapy. Trends Immunol. 2017;38(2):77–78.
   PubMed Web of Science ®Google Scholar
• Eleneen Y, Colen RR. Cancer imaging in immunotherapy. Adv Exp Med Biol. 2017;995:141–153.
   PubMed Web of Science ®Google Scholar
• Franklin C, Livingstone E, Roesch A, Schilling B and Schadendorf D. Immunotherapy in melanoma: recent advances and future directions. Eur J Surg Oncol. 2017;43(3):604–611.
   PubMed Web of Science ®Google Scholar
• Schultz LM, Majzner R, Davis KL, Davis KL and Mackall C. New developments in immunotherapy for pediatric solid tumors. Curr Opin Pediatr. 2018;30(1):30–39.
   PubMed Web of Science ®Google Scholar
• Okazaki T, Honjo T:PD-1. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19(7):813–824.
   PubMed Web of Science ®Google Scholar
• Zhu X, Lang J, Soluble PD-1. Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. Oncotarget. 2017;8(57):97671–97682.
   PubMedGoogle Scholar
• Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028.
   PubMed Web of Science ®Google Scholar
• Tsai KK, Zarzoso I, Daud AI. PD-1 and PD-L1 antibodies for melanoma. Hum Vaccines Immunother. 2014;10(11):3111–3116.
   PubMed Web of Science ®Google Scholar
• Peters S, Kerr KM, Stahel R:PD-1. PD-1 blockade in advanced NSCLC: a focus on pembrolizumab. Cancer Treat Rev. 2018;62:39–49.
   PubMed Web of Science ®Google Scholar
• Muenst S, Schaerli AR, Gao F, et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2014;146(1):15–24.
   PubMed Web of Science ®Google Scholar
• Wang Y, Lu JH, Wu QN, et al. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Mol Cancer. 2019;18(1):174.
   PubMed Web of Science ®Google Scholar
• You J, Cheng J, Yu B, Duan C and Peng J. Baicalin, a Chinese herbal medicine, inhibits the proliferation and migration of human Non-Small Cell Lung Carcinoma (NSCLC) cells, A549 and H1299, by activating the SIRT1/AMPK signaling pathway. Med Sci Monit. 2018;24:2126–2133.
   PubMed Web of Science ®Google Scholar
• McMullen ER, Gonzalez ME, Skala SL, et al. CCN6 regulates IGF2BP2 and HMGA2 signaling in metaplastic carcinomas of the breast. Breast Cancer Res Treat. 2018;172(3):577–586.
   PubMed Web of Science ®Google Scholar
• Xu X, Yu Y, Zong K, Lv P and Gu Y. Up-regulation of IGF2BP2 by multiple mechanisms in pancreatic cancer promotes cancer proliferation by activating the PI3K/Akt signaling pathway. J Exp Clin Cancer Res. 2019;38(1):497.
   PubMed Web of Science ®Google Scholar
• Bao Z, Chen L and Guo S. Knockdown of SLC34A2 inhibits cell proliferation, metastasis, and elevates chemosensitivity in glioma. J Cell Biochem. 2019;120(6):10205–10214.
   PubMed Web of Science ®Google Scholar
• Barra GB, Santa Rita TH, Almeida A, et al. Serum has higher proportion of Janus kinase 2 V617F mutation compared to paired EDTA-whole blood sample: a model for somatic mutation quantification using qPCR and the 2(-∆∆Cq) method. Diagnostics (Basel, Switzerland). 2020;10:153.
   PubMedGoogle Scholar
• Wang C, Hahn E, Slodkowska E, et al. Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types. Hum Pathol. 2018;82:131–139.
   PubMed Web of Science ®Google Scholar
• Hodgson A, Slodkowska E, Jungbluth A, et al. PD-L1 immunohistochemistry assay concordance in urothelial carcinoma of the bladder and hypopharyngeal squamous cell carcinoma. Am J Surg Pathol. 2018;42:1059.
   PubMed Web of Science ®Google Scholar
• Kulasinghe A, Perry C, Kenny L, et al. PD-L1 expressing circulating tumour cells in head and neck cancers. BMC Cancer. 2017;17(1):333.
   PubMedGoogle Scholar
• Gavrielatou N, Doumas S, Economopoulou P, Foukas PG and Psyrri A. Biomarkers for immunotherapy response in head and neck cancer. Cancer Treat Rev. 2020;84:101977.
   PubMed Web of Science ®Google Scholar
• Tan D, Sheng L and Yi QH. Correlation of PD-1/PD-L1 polymorphisms and expressions with clinicopathologic features and prognosis of ovarian cancer. Cancer Biomarkers. 2018;21(2):287–297.
   PubMed Web of Science ®Google Scholar
• He Y, Rozeboom L, Rivard CJ, et al. PD-1, PD-L1 protein expression in non-small cell lung cancer and their relationship with tumor-infiltrating lymphocytes. Med Sci Monit. 2017;23:1208–1216.
   PubMed Web of Science ®Google Scholar
• Wu Y, Cao D, Qu L, et al. PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer. Oncotarget. 2017;8(38):64066–64082.
   PubMedGoogle Scholar
• Wan B-S, Cheng M, Zhang L. Insulin-like growth factor 2 mRNA-binding protein 1 promotes cell proliferation via activation of AKT and is directly targeted by microRNA-494 in pancreatic cancer. World J Gastroenterol. 2019;25(40):6063–6076.
   PubMed Web of Science ®Google Scholar
• Abrenica B, AlShaaban M, Czubryt MP. The A-kinase anchor protein AKAP121 is a negative regulator of cardiomyocyte hypertrophy. J Mol Cell Cardiol. 2009;46(5):674–681.
   PubMed Web of Science ®Google Scholar
• Li T, Hu PS, Zuo Z, et al. METTL3 facilitates tumor progression via an m(6) A-IGF2BP2-dependentmechanism in colorectal carcinoma. Mol Cancer. 2019;18:112.
   PubMed Web of Science ®Google Scholar